Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Perini

Showing results (121-130 of 159) with videos related to

Pageof 16
Sort By:
The Lancet. Oncology|September 16, 2024
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 studyOthon Iliopoulos, Ane B Iversen, Vivek Narayan, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 3, 2006
Elevated plasma homocysteine in acute stroke was not associated with severity and outcome: stronger association with small artery diseaseF Perini, E Galloni, I Bolgan, et al.
The Lancet. Oncology|January 5, 2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 studyToni K Choueiri, Jaime R Merchan, Robert Figlin, et al.
The New England Journal of Medicine|November 24, 2021
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau DiseaseEric Jonasch, Frede Donskov, Othon Iliopoulos, et al.
The Lancet. Oncology|October 3, 2017
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun V Balar, Daniel Castellano, Peter H O'Donnell, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 18, 2007
Validation of AIDA Cefalee, a computer-assisted diagnosis database for the management of headache patientsR De Simone, G Coppola, A Ranieri, et al.
Cancer|October 11, 2013
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancerChristine A Ciunci, Rodolfo F Perini, Anjali N Avadhani, et al.
The Lancet. Oncology|July 14, 2023
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trialLaurence Albiges, Howard Gurney, Vagif Atduev, et al.
Japanese Journal of Clinical Oncology|January 16, 2025
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern AsiaHsiao-Jen Chung, Chihiro Kondoh, Woo Kyun Bae, et al.
International Journal of Cancer|June 9, 2023
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trialSun Young Rha, Toni K Choueiri, Vsevolod B Matveev, et al.
Pageof 16

Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
The Lancet. Oncology|September 16, 2024
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 studyOthon Iliopoulos, Ane B Iversen, Vivek Narayan, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 3, 2006
Elevated plasma homocysteine in acute stroke was not associated with severity and outcome: stronger association with small artery diseaseF Perini, E Galloni, I Bolgan, et al.
The Lancet. Oncology|January 5, 2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 studyToni K Choueiri, Jaime R Merchan, Robert Figlin, et al.
The New England Journal of Medicine|November 24, 2021
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau DiseaseEric Jonasch, Frede Donskov, Othon Iliopoulos, et al.
The Lancet. Oncology|October 3, 2017
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun V Balar, Daniel Castellano, Peter H O'Donnell, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 18, 2007
Validation of AIDA Cefalee, a computer-assisted diagnosis database for the management of headache patientsR De Simone, G Coppola, A Ranieri, et al.
Cancer|October 11, 2013
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancerChristine A Ciunci, Rodolfo F Perini, Anjali N Avadhani, et al.
The Lancet. Oncology|July 14, 2023
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trialLaurence Albiges, Howard Gurney, Vagif Atduev, et al.
Japanese Journal of Clinical Oncology|January 16, 2025
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern AsiaHsiao-Jen Chung, Chihiro Kondoh, Woo Kyun Bae, et al.
International Journal of Cancer|June 9, 2023
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trialSun Young Rha, Toni K Choueiri, Vsevolod B Matveev, et al.
Pageof 16